Trial Profile
A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms PIONEER-OLE
- Sponsors Abbott Laboratories; AbbVie
- 02 Apr 2021 Results assessing Baseline and week 12 plasma samples from the PIONEER studies were used to assess the levels of circulating proteins by multiplex assays and enzyme linked immunosorbent assays published in the British Journal of Dermatology
- 02 Nov 2018 According to an AbbVie media release, results from this study were presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
- 31 May 2018 Results published in the Journal of the American Academy of Dermatology.